novo nordisk semaglutide clinical trials announced headline results from STEP UP, a phase IIIb trial investigating subcutaneous 7.2 mg for obesity Novo Nordisk's semaglutide shows promise
Description
Bruising after semaglutide shots is a common concern for patients using this glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes or chronic weight management
At 0.25mg weekly, you draw 5 units per dose and use 1mg over four weeks, with 4mg remaining
According to the MHRA SmPC, semaglutide does not reduce the efficacy of hormonal contraceptives, though severe vomiting or diarrhoea may potentially affect the absorption of oral contraceptive pills, requiring temporary additional contraceptive measures
Godkendelse som lgemiddel i EU forventes tidligst i 2027
